Key clinical point: About half of patients with moderate to severe genital psoriasis said that their psoriasis had no impact on quality of life after 1 year of ixekizumab treatment.
Major finding: After 52 weeks of treatment, 46.7% of those continuously on ixekizumab and 50.8% of those who switched to ixekizumab from placebo at 12 weeks reported scores of 0 or 1 on the Dermatology Life Quality Index, indicating no impact of psoriasis on quality of life.
Study details: A randomized, double-blind placebo-controlled trial, followed by an open-label extension study out to 52 weeks of 139 adults with psoriasis affecting genital and nongenital areas.
Disclosures: Several authors reported financial relationships with multiple pharmaceutical companies, including Eli Lilly, which funded the study. Three coauthors are employees and shareholders of Eli Lilly.
REPORTING FROM WCD2019